Table 5. Alterations of CK18-Asp396 during second-, third- and fourth-line docetaxel therapy.
CK18-Asp396 increase (days 5–7)
|
CK18 increase (days 5–7)
|
||||
---|---|---|---|---|---|
(U l−1) | Percent increase | (U l−1) | Percent increase | (na) | |
Second docetaxel | 49 (0–115)b | 31.7 | 93 (−21–236) | 18.3 | 54/54 |
Third docetaxel | 22 (0–54) | 16.1 | 47 (−4–163) | 15.0 | 154/155 |
Fourth docetaxel | 34 (13–98) | 29.3 | 72 (2–202) | 30.8 | 14/15 |
(CK18-Asp396/CK18).
Median (25th–75th percentile) alterations from day 5 to day 7.
CK18=Cytokeratin 18.